IGC (IGC Pharma) ROCE %: -141.79% (As of Mar. 2026)


IGC IGC Pharma Inc IGC
29 GF Score
Price $0.27
GF Value $0.24
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is IGC Pharma ROCE %?

IGC Pharma IGC +1.79% 29 ROCE % is -141.79% as of Mar. 2026. GuruFocus rates IGC with a GF Score™ of 29/100 and a GF Value™ of $0.24 (Modestly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. IGC Pharma's annualized ROCE % for the quarter that ended in Mar. 2026 was -141.79%.

IGC Pharma  (AMEX:IGC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

IGC Pharma ROCE % Related Terms

IGC Pharma ROCE % Historical Data

* Premium members only.

The historical data trend for IGC Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IGC Pharma ROCE % Chart

IGC Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.82 -53.30 -58.33 -85.79 -105.98

IGC Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -87.49 -119.92 -160.53 -149.05 -141.79
IGC
29GF Score
IGC Pharma Inc IGC
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IGC Pharma ROCE % Calculation

IGC Pharma's annualized ROCE % for the fiscal year that ended in Mar. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=-7.446/( ( (9.902 - 2.34) + (8.747 - 2.257) )/ 2 )
=-7.446/( (7.562+6.49)/ 2 )
=-7.446/7.026
=-105.98 %

IGC Pharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-9.832/( ( (9.712 - 2.156) + (9.185 - 2.873) )/ 2 )
=-9.832/( ( 7.556 + 6.312 )/ 2 )
=-9.832/6.934
=-141.79 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -141.79% mean?
IGC Pharma (IGC) has a ROCE % of -141.79% as of Mar. 2026.
Is IGC Pharma's ROCE % too high?
IGC Pharma's current ROCE % is -141.79%. Overall, IGC Pharma has a GF Score™ of 29/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's ROCE % compare to CRVO and NEUP?
IGC Pharma's ROCE % of -141.79% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. IGC Pharma's current ROCE % is -141.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.27 — trading 11.1% above its estimated fair value. The current ROCE % is -141.79%. IGC Pharma's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For IGC Pharma (IGC), the current ROCE % is -141.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IGC Pharma (IGC) Overvalued in 2026?

Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued. The current stock price of $0.27 is trading 11.1% above its estimated GF Value™ of $0.24. GuruFocus considers IGC Pharma to be Modestly Overvalued.

Key valuation signals for IGC:

  • ROCE %: -141.79%
  • GF Value™: $0.24 vs. price of $0.27 (11.1% above fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IGC Pharma Business Description

Other Exchanges IGS1:Germany
Address 10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
29GF Score

Get the complete analysis for IGC

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.27
Price
$0.24
GF Value